Ardelyx Inc (ARDX) : Foresite Capital Management Ii reduced its stake in Ardelyx Inc by 8.39% during the most recent quarter end. The investment management company now holds a total of 428,989 shares of Ardelyx Inc which is valued at $4,324,209 after selling 39,308 shares in Ardelyx Inc , the firm said in a disclosure report filed with the SEC on Aug 12, 2016.Ardelyx Inc makes up approximately 2.74% of Foresite Capital Management Ii’s portfolio.
Other Hedge Funds, Including , Spark Investment Management sold out all of its stake in ARDX during the most recent quarter. The investment firm sold 54,500 shares of ARDX which is valued $549,360. Alliancebernstein added ARDX to its portfolio by purchasing 10,400 company shares during the most recent quarter which is valued at $104,832.Tiaa Cref Investment Management boosted its stake in ARDX in the latest quarter, The investment management firm added 12,916 additional shares and now holds a total of 71,759 shares of Ardelyx Inc which is valued at $723,331.Blackrock Institutional Trust Company N.a. boosted its stake in ARDX in the latest quarter, The investment management firm added 13,623 additional shares and now holds a total of 324,788 shares of Ardelyx Inc which is valued at $3,273,863.
Ardelyx Inc closed down -0.04 points or -0.39% at $10.31 with 1,81,121 shares getting traded on Monday. Post opening the session at $10.35, the shares hit an intraday low of $10.0701 and an intraday high of $10.4 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Ardelyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery development and commercialization of minimally-systemic small molecule therapeutics that work exclusively in the gastrointestinal (GI) tract to treat cardio-renal GI and metabolic diseases. The Company utilizing its platform discovered and designed its lead product candidate tenapanor which in clinical studies has demonstrated the ability to improve the symptoms of constipation-predominant irritable bowel syndrome (IBS-C) and to reduce the absorption of both dietary sodium and phosphorus. The Company in collaboration with AstraZeneca has completed a Phase IIb clinical trial evaluating tenapanor in patients with IBS-C. It also has other product candidates under development such as RDX002 for the treatment of Hyperphosphatemia RDX009 for the treatment of IBD Short Bowel Syndrome and non-alcoholic steatohepatitis (NASH) and RDX013 for the treatment of hyperkalemia.